EU Review Time Lengthens for BMS’s CAR-T Therapy Liso-Cel
Company Wants More Time To Answer Reviewers’ Questions
Bristol Myers Squibb's marketing application for liso-cel is in the final stages of the review process at the European Medicines Agency. The agency’s drug evaluation committee, the CHMP, adopted in mid-April the list of concerns it has with the application.
